Gandhi M, Meyer T W, Brooks D P
Department of Medicine, Palo Alto VA Health Care System and Stanford University, Palo Alto, Calif., USA.
Pharmacology. 1999 Aug;59(2):89-94. doi: 10.1159/000028308.
The effects of the selective angiotensin AT1 receptor antagonist, eprosartan, were evaluated in experimental renal disease. Five-sixth nephrectomy in male Munich-Wistar rats led to the development of hypertension, proteinuria and remnant glomerulosclerosis. Administration of the AT1 receptor antagonist, eprosartan, for 4 weeks resulted in inhibition of angiotensin II activity as confirmed by a reduced blood pressure response to exogenous angiotensin II challenge. Compared to vehicle treatment, eprosartan normalized blood pressure, reduced proteinuria and limited remnant glomerulosclerosis. These data suggest that eprosartan may provide a new tool in the treatment of progressive renal disease.
在实验性肾病中评估了选择性血管紧张素AT1受体拮抗剂依普罗沙坦的作用。雄性慕尼黑-维斯塔尔大鼠进行六分之五肾切除术后出现高血压、蛋白尿和残余肾小球硬化。给予AT1受体拮抗剂依普罗沙坦4周，可抑制血管紧张素II活性，这可通过对外源性血管紧张素II激发的血压反应降低得到证实。与赋形剂治疗相比，依普罗沙坦可使血压正常化、减少蛋白尿并限制残余肾小球硬化。这些数据表明依普罗沙坦可能为治疗进行性肾病提供一种新工具。
